Get the Stockscreener App
14.10
6.31%
-0.95
After Hours:
14.10
Amylyx Pharmaceuticals Inc stock is traded at $14.10, with a volume of 1.35M.
It is down -6.31% in the last 24 hours and up +8.55% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$15.05
Open:
$14.88
24h Volume:
1.35M
Relative Volume:
0.96
Market Cap:
$1.55B
Revenue:
$-665.00K
Net Income/Loss:
$-149.28M
P/E Ratio:
-7.8346
EPS:
-1.7997
Net Cash Flow:
$-154.52M
1W Performance:
-7.60%
1M Performance:
+8.55%
6M Performance:
+38.24%
1Y Performance:
+319.64%
1-Day Range:
$13.80
$14.88
1-Week Range:
$13.75
$15.70
52-Week Range:
$3.11
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-682-0917
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.10 | 1.65B | -665.00K | -149.28M | -154.52M | -1.7997 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.76 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.23 | 53.17B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.33 | 46.62B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.75 | 38.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.06 | 21.48B | 3.13B | 1.27B | 1.12B | 26.39 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx (AMLX) Q4 2025 Earnings Call Transcript - AOL.com
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com India
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Amylyx Leadership Triggers Buzz With Major Insider Stock Moves - TipRanks
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point (NASDAQ:AMLX) - Seeking Alpha
Tax-withholding sale by Amylyx Pharmaceuticals (AMLX) Chief Legal Officer - Stock Titan
Amylyx (AMLX) Co-CEO sells shares to cover RSU tax withholding - Stock Titan
Amylyx Pharmaceuticals (AMLX) CEO share sale covers tax obligations - Stock Titan
Amylyx (AMLX) CFO reports automatic tax-related sale of 7,909 shares - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $34.00 - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2025 Earnings Call Transcript - Insider Monkey
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following Narrower Losses And New Shelf Filings - simplywall.st
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress - Yahoo Finance
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout - MarketBeat
Page not foundAirwhon - MarketBeat
Amylyx Refocuses On Avexatide As LUCIDITY Milestone Raises Stakes - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Amylyx Pharmac - GuruFocus
Amylyx Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
AMLXForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Amylyx Pharmaceuticals at TD Cowen: Strategic Insights on Avexitide and More - Investing.com Canada
Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Amylyx Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Amylyx Pharmaceuticals Q4 2025 shows EPS beat By Investing.com - Investing.com India
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Quarterly Earnings Results - MarketBeat
Stifel Nicolaus Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals Q4 operating income USD -36.605 million versus. Ibes estimate USD -40.4 million - marketscreener.com
Amylyx Pharmaceuticals (AMLX) files S-3ASR shelf to sell stock, debt, warrants - Stock Titan
Amylyx Pharmaceuticals Q4 Operating Income USD -36.605 Million Versus. Ibes Estimate USD -40.4 Million - TradingView
Amylyx Pharmaceuticals announced that its current cash reserves are expected to be sufficient to support the company's operations, not only covering the potential commercialization process of the new drug Avexitide, but also sustaining operations through 20 - Bitget
Stifel Initiates Amylyx Pharmaceuticals at Buy With $21 Price Target - marketscreener.com
Amylyx Pharmaceuticals Q4 Net Loss Narrows - marketscreener.com
AMYLYX PHARMACEUTICALS ($AMLX) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss - marketscreener.com
Amylyx shares fall over 3% on trial uncertainty despite earnings beat By Investing.com - Investing.com Australia
Amylyx shares fall over 3% on trial uncertainty despite earnings beat - Investing.com Nigeria
Amylyx Pharmaceuticals 10-K: $0M Revenue, $(0.29)–$(0.31) EPS range not stated - TradingView
Amylyx (Nasdaq: AMLX) advances PBH, ALS and Wolfram drugs - Stock Titan
AMLX: Pivotal trial recruitment completed for avexitide in PBH; net loss narrowed and cash runway extends into 2028 - TradingView
Amylyx Pharmaceuticals (NASDAQ: AMLX) halves 2025 loss as PBH Phase 3 nears - Stock Titan
Press Release: Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - 富途牛牛
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Stifel initiates Amylyx stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Stifel initiates Amylyx stock with buy rating on drug potential - Investing.com Nigeria
AMLX (NASDAQ) insider sale: 22,522 shares from RSU vesting reported - Stock Titan
AMLX (NASDAQ: AMLX) reports 20,545 RSUs vesting and two insider sales in Feb–Mar 2026 - Stock Titan
Retail Surge: Can Amylyx Pharmaceuticals Inc outperform under higher oil pricesMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):